0001140361-16-088714.txt : 20161202 0001140361-16-088714.hdr.sgml : 20161202 20161202195229 ACCESSION NUMBER: 0001140361-16-088714 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20161130 FILED AS OF DATE: 20161202 DATE AS OF CHANGE: 20161202 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SANGAMO BIOSCIENCES INC CENTRAL INDEX KEY: 0001001233 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 680359556 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 501 CANAL BLVD STREET 2: POINT RICHMOND TECH CNTR. CITY: RICHMOND STATE: CA ZIP: 94804 BUSINESS PHONE: 5109706000 MAIL ADDRESS: STREET 1: 501 CANAL BLVD STREET 2: POINT RICHMOND TECH CNTR. CITY: RICHMOND STATE: CA ZIP: 94804 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Herberts Curt A. III CENTRAL INDEX KEY: 0001691262 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30171 FILM NUMBER: 162032464 MAIL ADDRESS: STREET 1: 501 CANAL BLVD. STREET 2: POINT RICHMOND TECH CENTER CITY: RICHMOND STATE: CA ZIP: 94804 3 1 doc1.xml FORM 3 X0206 3 2016-11-30 0 0001001233 SANGAMO BIOSCIENCES INC SGMO 0001691262 Herberts Curt A. III C/O SANGAMO BIOSCIENCES INC. POINT RICHMOND TECH CNTR. 501 CANAL BLVD RICHMOND CA 94804 0 1 0 0 Senior VP & CBO Common Stock 38152 D Employee Stock Option (Right to Buy) 3.99 2020-10-17 Common Stock 3646 D Employee Stock Option (Right to Buy) 5.12 2021-08-31 Common Stock 5000 D Employee Stock Option (Right to Buy) 2.55 2021-12-07 Common Stock 3000 D Employee Stock Option (Right to Buy) 5.41 2022-12-05 Common Stock 16146 D Employee Stock Option (Right to Buy) 12.12 2023-12-11 Common Stock 20000 D Employee Stock Option (Right to Buy) 14.07 2024-12-10 Common Stock 20000 D Employee Stock Option (Right to Buy) 8.87 2025-07-26 Common Stock 10000 D Employee Stock Option (Right to Buy) 9.41 2025-12-07 Common Stock 37500 D Includes (i) 3,333 shares subject to restricted stock units granted on December 12, 2013 which will vest upon the Reporting Person's continued service with the Issuer through December 12, 2016, (ii) 6,666 shares subject to restricted stock units granted on December 11, 2014 which will vest in two (2) equal installments upon the Reporting Person's continued service with the Issuer through December 11, 2016 and December 11, 2017, and (iii) 18,750 shares subject to restricted stock units granted on December 8, 2015 which will vest in three (3) equal installments upon the Reporting Person's continued service with the Issuer during the three (3) year period measured from the grant date. The shares underlying the stock option are fully vested and exercisable. The shares underlying the stock option will be fully vested and exercisable on December 5, 2016, provided that the Reporting Person remains in service with the Issuer through such vesting date. One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from the December 12, 2013 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from the December 11, 2014 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. One-quarter (1/4) of the option shares vested and became exercisable upon completion of one (1) year of service by the Reporting Person measured from the July 27, 2015 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. One-quarter (1/4) of the option shares will vest and become exercisable upon completion of one (1) year of service by the Reporting Person measured from the December 8, 2015 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date. /s/ Florence Tam, Attorney-in-Fact 2016-12-02 EX-24 2 herberts_poa.htm POWER OF ATTORNEY
POWER OF ATTORNEY


Know all by these presents, that the undersigned hereby constitutes and appoints Florence Tam with full power of substitution, the undersigned's true and lawful attorney-in-fact to:

1.  execute for and on behalf of the undersigned , in the undersigned's capacity as an officer or director, as the case may be, of Sangamo BioSciences, Inc. (the "Company"), Forms 3, 4 and 5 (and any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the rules thereunder;

2.   do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5, complete and execute any amendments thereto, and timely file such form with the U.S. Securities and Exchange Commission (the "SEC") and any securities exchange or similar authority, including without limitation the filing of a Form ID or any other documents necessary or appropriate to enable the undersigned to file the Forms 3, 4 and 5 electronically with the SEC;

3.   seek or obtain, as the undersigned's representative and on the undersigned's behalf, information on transactions in the Company's securities from any broker or financial institution, and the undersigned hereby authorizes any such person to release any such information to each of the undersigned's attorneys-in-fact appointed by this Power of Attorney and approves and ratifies any such release of information; and

4.   take any other action in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by or for, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such information and disclosure as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever required, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in- fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted.

The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request and on the behalf of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with, or any liability for the failure to comply with, any provision of Section 16 of the Exchange Act.


This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 or 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to each of the foregoing attorneys-in-fact.


IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 28 day of November 2016.


 
Signature:
   
 
/s/ Curt A. Herberts III                             
 
Curt A. Herberts III